# amyotrophic lateral sclerosis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/amyotrophic-lateral-sclerosis

> 2 upcoming FDA catalysts in amyotrophic lateral sclerosis: ibudilast (MNOV) on April 2027 (primary completion); ibudilast (MNOV) on Apr to Jul 2027 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2026 | [INS1202 trial start](https://sec-api.dev/pdufa/ins1202) | INSM | amyotrophic lateral sclerosis | completed | "In January 2026, the Company dosed the first patient in the Phase 1 ARMOR study of INS1202, an intrathecally delivered gene therapy for patients with amyotrophic lateral sclerosis (ALS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/ef20066055_ex99-1.htm)) |
| June 17, 2026 | [ION363 primary completion](https://sec-api.dev/pdufa/ion363) | IONS | Amyotrophic Lateral Sclerosis | completed | "NCT04768972 (FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-17 (ACTUAL); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04768972)) |
| August 12, 2026 | [ARGX-119 primary completion](https://sec-api.dev/pdufa/argx-119) | ARGX | Amyotrophic Lateral Sclerosis | withdrawn | "NCT06441682 (A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06441682)) |
| October 2026 | [Dazucorilant 300 mg primary completion](https://sec-api.dev/pdufa/dazucorilant) | CORT | Amyotrophic Lateral Sclerosis | delayed | "NCT05407324 (Dazucorilant in Patients With Amyotrophic Lateral Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05407324)) |
| Oct 2026 to Jan 2027 | [Dazucorilant 300 mg topline data readout](https://sec-api.dev/pdufa/dazucorilant) | CORT | Amyotrophic Lateral Sclerosis | scheduled | "NCT05407324 (Dazucorilant in Patients With Amyotrophic Lateral Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05407324)) |
| October 19, 2026 | [CNM-Au8 (cnm-au8) NDA/BLA submission](https://sec-api.dev/pdufa/cnm-au8) | CLNN | amyotrophic lateral sclerosis | completed | "SALT LAKE CITY, October 19, 2026 — Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced that it has submitted a New Drug Application (NDA) earlier in October to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of CNM-Au8® for the treatment of amyotrophic lateral sclerosis (ALS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926032882/ex_1027473.htm)) |
| April 2027 | [Ibudilast primary completion](https://sec-api.dev/pdufa/ibudilast) | MNOV | Amyotrophic Lateral Sclerosis | scheduled | "NCT04057898 (Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor MediciNova." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04057898)) |
| Apr to Jul 2027 | [Ibudilast topline data readout](https://sec-api.dev/pdufa/ibudilast) | MNOV | Amyotrophic Lateral Sclerosis | scheduled | "NCT04057898 (Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor MediciNova." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04057898)) |

## Drugs

- [INS1202](https://sec-api.dev/pdufa/ins1202) (INSM)
- [ION363](https://sec-api.dev/pdufa/ion363) (IONS)
- [ARGX-119](https://sec-api.dev/pdufa/argx-119) (ARGX)
- [Dazucorilant 300 mg](https://sec-api.dev/pdufa/dazucorilant) (CORT)
- [CNM-Au8 (cnm-au8)](https://sec-api.dev/pdufa/cnm-au8) (CLNN)
- [Ibudilast](https://sec-api.dev/pdufa/ibudilast) (MNOV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/amyotrophic-lateral-sclerosis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "amyotrophic lateral sclerosis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/amyotrophic-lateral-sclerosis

```bibtex
@misc{secapidev_indications_amyotrophic_lateral_sclerosis_20261116,
  title        = {amyotrophic lateral sclerosis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/amyotrophic-lateral-sclerosis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_amyotrophic_lateral_sclerosis_20261116","title":"amyotrophic lateral sclerosis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/amyotrophic-lateral-sclerosis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
